Back to Journals » Cancer Management and Research » Volume 11

Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients

Authors Auezova R, Ivanova N, Akshulakov S, Zhetpisbaev B, Kozhakhmetova A, Ryskeldiyev N, Mustafin K, Teltayev D, Auezova L

Received 23 November 2018

Accepted for publication 5 February 2019

Published 15 April 2019 Volume 2019:11 Pages 3227—3236


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Antonella D'Anneo

Raushan Auezova,1 Natalia Ivanova,2 Serik Akshulakov,1 Berik Zhetpisbaev,1 Aizhan Kozhakhmetova,1 Nurzhan Ryskeldiyev,1 Khalit Mustafin,1 Daniyar Teltayev,1 Lizette Auezova3

1Department of Pathology of the Central Nervous System, National Center for Neurosurgery, Astana, Kazakhstan; 2Scientific Department, Polenov Russian Scientific Research Institute of Neurosurgery (a branch of Federal Almazov North-West Medical Research Center), Ministry of Health of the Russian Federation, Saint-Petersburg, Russia; 3Bioactive Molecules Research Group, Department of Chemistry and Biochemistry, Faculty of Sciences-II, Lebanese University, Beirut, Lebanon

Background: Glioma patients with mutant isocitrate dehydrogenase have improved survival; this could be in part due to the suppressive effect of mutant IDH on the level of chronic inflammation. This study aimed to prospectively analyze the association of IDH1 mutation status with preoperative levels of blood inflammatory markers: neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR), C-reactive protein (CRP), and red cell distribution width (RDW) in gliomas.
Patients and methods: Receiver operating characteristic curves for cutoff value determination, various bivariate tests, and survival analyses (Kaplan–Meier curves and Cox regression) were performed.
Results: Patients with mutant IDH1 had reduced levels of NLR (P<0.032) and CRP (P<0.008). Moreover, these patients showed better median overall survival compared to those without IDH1 mutation (P<0.000). In univariate analysis, IDH1 mutation status (P<0.000), NLR (P<0.000), PLR (P<0.008), and CRP (P<0.001) were among the factors associated with survival. By multivariate analysis, IDH1 mutation (P<0.044) and NLRP<0.022) remained independent factors associated with better survival; other independent variables were tumor grade (P<0.000) and location in noneloquent area (P<0.015).
Conclusion: The obtained results show that IDH1 mutation is associated with lower levels of chronic inflammation that could account for an improved prognosis in this group of patients.

Keywords: glioma, IDH, inflammation, neutrophil–lymphocyte ratio, survival

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]